Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

 


A PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA


Trial Focus

Multiple Myeloma/Plasma Cell Tumors

Objective

         This is a clinical trial of pomalidomide that will be administered by mouth which is investigational and bortezomib and low-dose dexamethasone that will be administered by I.V. and mouth and is standard of care.

IRB Protocol #

13-2056

Trial Status

OPEN

Principle Investigator

CLAY SMITH

Sponsor

Celgene Corporation

Contact

AARON FULLERTON at -- or --

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to when your disease worsens. A follow up period will consist of phone contact, physician contact, or clinic visit. // Eligibility criteria include but are not limited to 18 years or older with multiple myeloma.Eligibility criteria include but are not limited to 18 years or older with multiple myeloma.